PMLiVE9d
Novo Nordisk’s GLP-1 drug semaglutide shows promise in fatty liver disease MASH
Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
PMLiVE6d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
Business Wire15d
PopVax Announces 1.15 Million USD in Funding from the Bill & Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...
TheStreet.com14d
Nanovation Microtech Inc
Google parent Alphabet overcame a key investor concern as it posted stronger-than-expected third quarter earnings.
emjreviews.com23d
Transforming Care in SEA: Evidence and Considerations for Evolution of the Current Treatment Paradigm
Nanovation Therapeutics, Olympus Medical, Pulmonx, Roche Diagnostics, and Uptake Medical. Korn has received research support from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Novartis, ...
The New York Times16h
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...